Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Account Payables (2016 - 2025)

Ani Pharmaceuticals' Change in Account Payables history spans 14 years, with the latest figure at -$7.2 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 6.07% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached $15.2 million, up 3064.09%, while the annual FY2025 figure was $15.2 million, 3064.09% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$7.2 million at Ani Pharmaceuticals, down from $13.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $13.8 million in Q3 2025 and bottomed at -$9.1 million in Q3 2022.
  • The 5-year median for Change in Account Payables is $2.6 million (2021), against an average of $1.9 million.
  • The largest YoY upside for Change in Account Payables was 753.23% in 2022 against a maximum downside of 602.32% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $9.8 million in 2021, then rose by 3.02% to $10.1 million in 2022, then plummeted by 72.38% to $2.8 million in 2023, then tumbled by 345.36% to -$6.8 million in 2024, then decreased by 6.07% to -$7.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Change in Account Payables are -$7.2 million (Q4 2025), $13.8 million (Q3 2025), and $3.1 million (Q2 2025).